StockTipsArenaBeta

BUY Aurobindo Pharma — Prakash Gaba

BUYAurobindo Pharma
Aurobindo Pharma share price target & all analyst calls

byPrakash GabaHorizon: Swing (≤2wk)8 Sept 2026via CNBC Awaaz.

Entry₹1,678.6Inferred
Target₹1,700
Total upside +1.27% (call closed)
Stop loss₹1,670-0.51% risk
Exit₹1,7009 Sept 2026, 9:25 am
Target hit+1.27%0.00%upside left
Follow Prakash Gaba for new calls(30% target hit, 299 closed calls)Get alertsWatch AUROPHARMA for new buy/sell callsGet alertsSee 1 active Swing call on AUROPHARMASee 149 active Swing picks this week

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

Frozen at close · 9 Sept 2026
5 supporting3 neutral2 opposing
Supports the BUY call (5)

3 other SEBI-registered advisors have active swing BUY calls on this stock, all issued in the last 14 days

Advisor consensus · same horizon·8 Sept · today

Aurobindo stock gains on generic Advair launch

NewsGoogle News·1 Sept · 1w ago

(opens in new tab)

Aurobindo Pharma gains over 3% as subsidiary launches generic Advair Diskus in US; stock up 41% YTD

NewsEt-Markets·31 Aug · 1w ago

(opens in new tab)

Aurobindo Pharma's subsidiary, Lannett Company LLC, has launched a generic version of Advair Diskus® in the US. This product is used to treat asthma and COPD.

NSE · Press Release·31 Aug · 1w ago

(opens in new tab)

Aurobindo Pharma's subsidiary, Lannett Company LLC, has launched a generic version of Advair Diskus in the US. This marks the first product from Aurobindo's inhalation pipeline to be commercialized in

BSE · Company Update·31 Aug · 1w ago

(opens in new tab)
Neutral / worth noting (3)

Aurobindo Pharma arm Apitoria incorporates Avogent Lifesciences as subsidiary

NewsGoogle News·1 Sept · 1w ago

(opens in new tab)

Aurobindo Pharma Ltd's wholly owned subsidiary, Apitoria Pharma Private Limited, has incorporated a new wholly owned subsidiary named Ávogent Lifesciences Private Limited.

BSE · Company Update·1 Sept · 1w ago

(opens in new tab)

Aurobindo Pharma’s API plant gets three US FDA observations after inspection

NewsCnbc-Tv18·28 Aug · 2w ago

(opens in new tab)
Weighs against the BUY call (2)

USFDA Issues Three Observations To Aurobindo Pharma Arm's Facility In Andhra

NewsNdtv-Profit·28 Aug · 2w ago

(opens in new tab)

1 advisor has an active short-term SELL call on this stock

Advisor consensus · adjacent horizon·6 Aug · 1mo ago

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

Other calls on Aurobindo Pharma

All analyst calls on Aurobindo Pharma

More from Prakash Gaba

Every call and its outcome